$STEK
Stemtech Corp Stock $stek

$stek Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000168316823008596 Filed on December 01, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$1.362M	$1.298M	$1.047M
YoY Change	26.13%	24.0%	15.33%
Cost Of Revenue	$219.8K	$290.9K	$180.6K
YoY Change	-32.92%	61.07%	42.85%
Gross Profit	$1.142M	$1.007M	$866.4K
YoY Change	51.85%	16.27%	10.88%
Gross Profit Margin	83.86%	77.59%	82.75%
Selling, General & Admin	$2.190M	$1.200M	$3.943M
YoY Change	143.77%	-69.55%	184.93%
% of Gross Profit	191.74%	119.15%	455.04%
Research & Development	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit	0.0%	0.0%	0.0%
Depreciation & Amortization	$155.8K	$158.6K	$113.5K
YoY Change	32.87%	39.76%	-65.01%
% of Gross Profit	13.64%	15.74%	13.09%
Operating Expenses	$2.569M	$1.586M	$4.249M
YoY Change	116.92%	-62.66%	180.05%
Operating Profit	-$1.427M	-$579.0K	-$3.382M
YoY Change	230.13%	-82.88%	359.72%
Interest Expense	-$456.2K	-$426.1K	$16.40M
YoY Change	123.42%	-102.6%	-455.46%
% of Operating Profit
Other Income/Expense, Net	$19.11K	-$427.6K	$20.77M
YoY Change	3085.0%	-102.06%	72823.58%
Pretax Income	-$1.864M	-$1.007M	$17.39M
YoY Change	317.83%	-105.79%	-426.83%
Income Tax	$0.00	$33.53K
% Of Pretax Income
Net Earnings	-$1.865M	-$1.042M	$17.42M
YoY Change	259.4%	-105.98%	-428.04%
Net Earnings / Revenue	-136.94%	-80.24%	1663.46%
Basic Earnings Per Share		-$0.01	$0.38
Diluted Earnings Per Share	-$0.02	-$0.01	$0.38
COMMON SHARES
Basic Shares Outstanding	104.5M shares	100.2M shares	44.80M shares
Diluted Shares Outstanding		100.6M shares	45.59M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$114.2K	$323.6K	$123.1K
YoY Change	-13.83%	162.92%	-92.3%
Cash & Equivalents	$114.2K	$323.6K	$123.1K
Short-Term Investments
Other Short-Term Assets	$176.7K	$184.4K	$255.1K
YoY Change	-38.43%	-27.71%	-31.46%
Inventory	$48.33K	$84.08K	$181.8K
Prepaid Expenses
Receivables	$61.49K	$102.7K	$39.75K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$400.7K	$694.7K	$599.7K
YoY Change	-34.56%	15.85%	-71.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.06K	$15.19K	$30.70K
YoY Change	-63.16%	-50.53%	-71.09%
Goodwill	$467.4K	$467.4K	$467.4K
YoY Change	0.0%	0.0%
Intangibles	$2.711M	$2.861M	$3.097M
YoY Change	-9.47%	-7.61%
Long-Term Investments	$23.71K	$23.59K	$28.42K
YoY Change	2.77%	-17.0%	-35.47%
Other Assets
YoY Change
Total Long-Term Assets	$3.283M	$3.454M	$3.751M
YoY Change	-10.18%	-7.91%	-9.29%
TOTAL ASSETS
Total Short-Term Assets	$400.7K	$694.7K	$599.7K
Total Long-Term Assets	$3.283M	$3.454M	$3.751M
Total Assets	$3.683M	$4.149M	$4.351M
YoY Change	-13.68%	-4.64%	-30.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.709M	$2.650M	$3.868M
YoY Change	-20.25%	-31.49%	40.99%
Accrued Expenses	$66.87K	$83.84K	$62.02K
YoY Change	-43.84%	35.18%	-86.95%
Deferred Revenue
YoY Change
Short-Term Debt	$3.630M	$3.029M	$1.631M
YoY Change	217.5%	85.68%	148.15%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.462M	$5.846M	$8.995M
YoY Change	-12.86%	-35.01%	39.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$0.00	$0.00	$71.55K
YoY Change	-100.0%	-100.0%	-98.2%
Total Long-Term Liabilities	$0.00	$0.00	$71.55K
YoY Change	-100.0%	-100.0%	-98.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.462M	$5.846M	$8.995M
Total Long-Term Liabilities	$0.00	$0.00	$71.55K
Total Liabilities	$6.462M	$5.846M	$9.067M
YoY Change	-13.13%	-35.52%	-9.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.06M	-$25.20M	-$21.11M
YoY Change	25.1%	19.35%
Common Stock	$105.0K	$104.5K	$48.63K
YoY Change	-99.46%	114.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.039M	-$956.8K	-$4.001M
YoY Change
Total Liabilities & Shareholders Equity	$3.683M	$4.149M	$4.351M
YoY Change	-13.68%	-4.64%	-30.68%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$1.865M	-$1.042M	$17.42M
YoY Change	259.4%	-105.98%	-428.04%
Depreciation, Depletion And Amortization	$155.8K	$158.6K	$113.5K
YoY Change	32.87%	39.76%	-65.01%
Cash From Operating Activities	-$1.132M	-$5.320K	-$231.4K
YoY Change	370.1%	-97.7%	-69.43%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	270.8K	268.6K	361.1K
YoY Change	-253.9%	-25.61%	-82.12%
NET CHANGE
Cash From Operating Activities	-1.132M	-5.320K	-231.4K
Cash From Investing Activities
Cash From Financing Activities	270.8K	268.6K	361.1K
Net Change In Cash	-861.2K	263.3K	129.7K
YoY Change	106.63%	102.97%	-89.73%
FREE CASH FLOW
Cash From Operating Activities	-$1.132M	-$5.320K	-$231.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2151440
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4851 Tamiami Trail North, Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Naples
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34103
	dei	City Area Code CityAreaCode	(954)
	dei	Local Phone Number LocalPhoneNumber	715-6000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	STEK
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001511820
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	STEK	Settlement Of Accrued Liabilities For Common Stock SettlementOfAccruedLiabilitiesForCommonStock		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-172172
	dei	Entity Registrant Name EntityRegistrantName	STEMTECH CORPORATION
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	104476731	shares
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	323629	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132487	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	102647	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	34767	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	84079	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	158053	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	184377	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	287063	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	694732	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	612370	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15189	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27296	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2861183	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2994000	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	23593	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	23065	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	86916	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	142801	usd
CY2023Q3	us-gaap	Goodwill Goodwill	467409	usd
CY2022Q4	us-gaap	Goodwill Goodwill	467409	usd
CY2023Q3	us-gaap	Assets Assets	4149022	usd
CY2022Q4	us-gaap	Assets Assets	4266941	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2650165	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3396543	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1360313	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	446246	usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1392972	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	482885	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	83836	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	119065	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	82835	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	39170	usd
CY2023Q3	STEK	Factoring Liability FactoringLiability	276028	usd
CY2022Q4	STEK	Factoring Liability FactoringLiability	214249	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2717633	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5846149	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7415791	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23068	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5846149	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7438859	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	104476731	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	104476731	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53442147	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53442147	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	104477	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	53442	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24596604	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19391400	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-461225	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-247760	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25196690	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21631241	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-956834	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2434159	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-740293	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-737759	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1697127	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3171918	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4149022	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4266941	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1298322	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1047030	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3559789	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3479762	usd
CY2023Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	265162	usd
CY2022Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	160509	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	719879	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	789566	usd
CY2023Q3	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	25734	usd
CY2022Q3	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	20090	usd
	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	62016	usd
	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	46843	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	290896	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	180599	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	781895	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	836409	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1007426	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	866431	usd
	us-gaap	Gross Profit GrossProfit	2777894	usd
	us-gaap	Gross Profit GrossProfit	2643353	usd
CY2023Q3	STEK	Commission Expenses CommissionExpenses	386070	usd
CY2022Q3	STEK	Commission Expenses CommissionExpenses	306293	usd
	STEK	Commission Expenses CommissionExpenses	807678	usd
	STEK	Commission Expenses CommissionExpenses	761345	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	119123	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	120434	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	387102	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	400018	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1081224	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3822131	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4366912	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6073133	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13800	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1586417	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4248858	usd
	us-gaap	Operating Expenses OperatingExpenses	5575492	usd
	us-gaap	Operating Expenses OperatingExpenses	7234496	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-578991	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3382427	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2797598	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4591143	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1525	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9284	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2626	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7333	usd
CY2023Q3	us-gaap	Interest Expense Other InterestExpenseOther	426048	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	1833911	usd
	us-gaap	Interest Expense Other InterestExpenseOther	4323528	usd
	us-gaap	Interest Expense Other InterestExpenseOther	3004928	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	18229091	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1681798	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-4112025	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4237648	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	814132	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3358842	usd
CY2023Q3	STEK	Gain On Settlement Of Derivative Liabilities GainOnSettlementOfDerivativeLiabilities	0	usd
CY2022Q3	STEK	Gain On Settlement Of Derivative Liabilities GainOnSettlementOfDerivativeLiabilities	0	usd
	STEK	Gain On Settlement Of Derivative Liabilities GainOnSettlementOfDerivativeLiabilities	1059839	usd
	STEK	Gain On Settlement Of Derivative Liabilities GainOnSettlementOfDerivativeLiabilities	0	usd
CY2023Q3	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	0	usd
CY2022Q3	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	126525	usd
	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	0	usd
	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	250825	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-427573	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20768637	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-770385	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3499953	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1006564	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	17386210	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3567983	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8091096	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33529	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1040093	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	17386210	usd
	us-gaap	Profit Loss ProfitLoss	-3567983	usd
	us-gaap	Profit Loss ProfitLoss	-8091096	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1707	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-30707	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2534	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-65034	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1041800	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	17416917	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3565449	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8026062	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100572563	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45588294	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76221547	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44983240	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100572563	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45588294	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76221547	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44983240	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1041800	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	17416917	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3565449	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8026062	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	223557	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	406374	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	213465	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	243667	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1265357	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	17010543	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3778914	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8269729	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28772322	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	110665	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2806111	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	638000	usd
CY2022Q3	STEK	Stock Issued For Loan Extension StockIssuedForLoanExtension	3321774	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-406374	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-30707	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	17416917	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4715936	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	328388	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2836111	usd
	STEK	Stock Issued For Loan Extension StockIssuedForLoanExtension	3621774	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	638000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-243667	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-65034	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8026062	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4715936	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1310037	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	110665	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1838	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	764057	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-223557	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1707	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1041800	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1697127	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3171918	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	328388	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	433951	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	2403453	usd
	STEK	Settlement Of Accrued Liabilities For Common Stock SettlementOfAccruedLiabilitiesForCommonStock	807076	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	271920	usd
	us-gaap	Derivative Instruments Gain Loss Reclassification From Accumulated Oci To Income Estimated Net Amount To Be Transferred DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred	1011451	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-213465	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2534	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3565449	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1697127	usd
	us-gaap	Profit Loss ProfitLoss	-3567983	usd
	us-gaap	Profit Loss ProfitLoss	-8091096	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	432049	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	330169	usd
	STEK	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	55885	usd
	STEK	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	46388	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	328388	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	328388	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	433951	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2836111	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2443506	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2400670	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1681798	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-4112025	usd
	STEK	Noncash Interest Expense From Issuance On Debt Derivative NoncashInterestExpenseFromIssuanceOnDebtDerivative	1604081	usd
	STEK	Noncash Interest Expense From Issuance On Debt Derivative NoncashInterestExpenseFromIssuanceOnDebtDerivative	0	usd
	STEK	Gain Loss On Settlement Of Derivative Liabilities GainLossOnSettlementOfDerivativeLiabilities	1059839	usd
	STEK	Gain Loss On Settlement Of Derivative Liabilities GainLossOnSettlementOfDerivativeLiabilities	-0	usd
	STEK	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPppLoans	-0	usd
	STEK	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPppLoans	250825	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	814132	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3358842	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	67880	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29034	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-73974	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-254608	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-102686	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-69652	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	828263	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	406600	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	528	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-10276	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-58297	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-41240	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	43665	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-904009	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-976150	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1711000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	341939	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	403293	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	67228	usd
	STEK	Net Proceeds From Financing Arrangement NetProceedsFromFinancingArrangement	909	usd
	STEK	Net Proceeds From Financing Arrangement NetProceedsFromFinancingArrangement	239986	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1308616	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	514697	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-213465	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-243667	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	191142	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-705120	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132487	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	828206	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	323629	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123086	usd
	us-gaap	Interest Paid Net InterestPaidNet	46243	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	STEK	Stock Issued For Lfr Acquisition StockIssuedForLfrAcquisition	271920	usd
	STEK	Stock Issued For Lfr Acquisition StockIssuedForLfrAcquisition	0	usd
	STEK	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt	2403453	usd
	STEK	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt	0	usd
	STEK	Settlement Of Accrued Liabilities For Common Stocks SettlementOfAccruedLiabilitiesForCommonStocks	807076	usd
	STEK	Settlement Of Accrued Liabilities For Common Stocks SettlementOfAccruedLiabilitiesForCommonStocks	0	usd
	STEK	Reclassification Of Derivative Liabilities To Apic ReclassificationOfDerivativeLiabilitiesToApic	1011451	usd
	STEK	Reclassification Of Derivative Liabilities To Apic ReclassificationOfDerivativeLiabilitiesToApic	0	usd
	STEK	Recognition Of Right Of Use Asset Operating Lease RecognitionOfRightOfUseAssetOperatingLease	0	usd
	STEK	Recognition Of Right Of Use Asset Operating Lease RecognitionOfRightOfUseAssetOperatingLease	53463	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_zvUo4Z9zpE6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_823_zpMNegqpW6qb">Organization and Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stemtech Corporation and its Subsidiaries (collectively, the “<b>Company</b>”) was incorporated in the State of Nevada, USA on September 4, 2009 under the previous name Globe Net Wireless Corp. On November 19, 2021, the Company adopted an Amendment to its Articles changing the name of the Corporation to Stemtech Corporation in the state of Nevada, and on April 14, 2022, FINRA gave final approval for said name change, as evidenced by the 8-K filed that date. Stemtech is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in stem cell science, and believes it can demonstrate that adult stem cells function as the natural renewal system of the body. The Company believes our products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. Our mission is to enhance wellness and prosperity around the world. These products are marketed internationally by the Company’s subsidiaries and through independent distributors. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, OraStem® (Oral Health Care), D-Fuze™ (Electromagnetic Frequency Blocker), Cellect One™ Rapid Renew Stem Cell Peptide Night Cream.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2021, Stemtech Corporation (“<b>Stemtech</b>”), a Delaware corporation, entered into a Merger Agreement (the “<b>Merger Agreement</b>”) with Globe Net Wireless Corp. (“<b>Globe Net</b>” or “<b>GNTW</b>”). The merger was accounted for as a reverse acquisition and recapitalization in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, <i>Business Combinations</i>. Management evaluated the guidance contained in ASC 805 with respect to the identification of the acquirer in the merger and concluded, based on a consideration of the pertinent facts and circumstances, that Stemtech acquired Globe Net for financial accounting purposes. On November 9, 2021, the Company changed its fiscal year end from a fiscal year end of August 31 to a calendar year end of December 31.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Stemtech (Parent) and its ten (10) subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="width: 97%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech HealthSciences Corp (U.S.A.) (“Stemtech HealthSciences”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Canada, Inc. (“Canada”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Health Sciences S. de R.L. de C.V. (“Mexico”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Services SARL de C.V. (Mexico) (“Stemtech Mexico”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Malaysia Holdings Sdn. Bhd. (“Malaysia Holdings”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Malaysia Sdn. Bhd. (“Malaysia”) – 70%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Taiwan Holding, Inc. (“Taiwan”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tecrecel S.A. (“Ecuador”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Food & Health Tech Foodhealth SA (“Ecuador FHTFH”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life Factor Research (“LFR”) – 100%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"> </p>
CY2023Q3	STEK	Working Capital WorkingCapital	-5200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_z9btC3gRqaV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_865_zeErGlf0xfYa">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14448206	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3836000	shares
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	84079	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	103297	usd
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	0	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	54756	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	84079	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	158053	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2338142	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1918200	usd
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	2861183	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	2994000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	19963	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	61156	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y11M12D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	23810	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64935	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	88745	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4909	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	83836	usd
CY2022	STEK	Proceeds From Factoring Liability ProceedsFromFactoringLiability	528984	usd
	STEK	Proceeds From Factoring Liability ProceedsFromFactoringLiability	953786	usd
	STEK	Cash Received For Future Receivables CashReceivedForFutureReceivables	766111	usd
CY2023Q3	STEK	Factoring Liability Gross FactoringLiabilityGross	240895	usd
CY2022Q4	STEK	Factoring Liability Gross FactoringLiabilityGross	292636	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	2753285	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	929131	usd
CY2023Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.13	pure
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.05
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	171362	usd
CY2023Q2	STEK	Agreed To Issued Shares AgreedToIssuedShares	7739938	shares
CY2023Q2	us-gaap	Shares Issued SharesIssued	5121200	shares
CY2023Q2	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	79212	usd
CY2021Q4	STEK	Derivative Liabilities1 DerivativeLiabilities1	4224585	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	5366289	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	-10096512	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	3223271	usd
CY2022Q4	STEK	Derivative Liabilities1 DerivativeLiabilities1	2717633	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	2512936	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	-3548771	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-1681798	usd
CY2023Q3	STEK	Derivative Liabilities1 DerivativeLiabilities1	0	usd
CY2023Q3	STEK	Factoring Liability Discount FactoringLiabilityDiscount	35133	usd
CY2022Q4	STEK	Factoring Liability Discount FactoringLiabilityDiscount	78387	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	25000000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	21000000	usd

Files In Submission

Name	View Source	Status
stek-20230930_def.xml	Edgar Link	unprocessable
stek-20230930_pre.xml	Edgar Link	unprocessable
0001683168-23-008596-index-headers.html	Edgar Link	pending
0001683168-23-008596-index.html	Edgar Link	pending
0001683168-23-008596.txt	Edgar Link	pending
0001683168-23-008596-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stek-20230930.xsd	Edgar Link	pending
stemtech_ex3101.htm	Edgar Link	pending
stemtech_ex3102.htm	Edgar Link	pending
stemtech_ex3201.htm	Edgar Link	pending
stemtech_ex3202.htm	Edgar Link	pending
stemtech_i10q-93023.htm	Edgar Link	pending
stek-20230930_cal.xml	Edgar Link	unprocessable
stek-20230930_lab.xml	Edgar Link	unprocessable
stemtech_i10q-93023_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STEK
Stemtech Corp Stock $stek

2023 Q4 Form 10-Q Financial Statement

#000168316823008596 Filed on December 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK Stemtech Corp Stock $stek

2023 Q4 Form 10-Q Financial Statement

#000168316823008596 Filed on December 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK
Stemtech Corp Stock $stek